• PTC Therapeutics

  Participated · Equity · Mar 2013

  PTC Therapeutics is a biopharmaceutical company focused on discovery, development and commercialization of orally administered proprietary small-molecule drugs that target post-transcriptional control processes. Its lead program is ataluren, which the company is developing for nonsense mutation Duchenne muscular dystrophy (nmDMD) and nonsense mutation cystic fibrosis (nmCF). PTC has worldwide development and commercial rights to ataluren in all indications and territories. The company recently completed a $60M financing to support continued clinical development of ataluren. PTC is initiating a Phase 3 confirmatory trial of ataluren in nmDMD with the goal of commencing enrollment in the first half of 2013. The company is led by CEO Stuart W. Peltz, Ph.D. PTC Therapeutics is a South Plainfield, NJ‑based biopharmaceutical company focused on discovering, developing and commercializing orally administered small‑molecule drugs that target post‑transcriptional control processes. Its lead program is ataluren, which is in late‑stage clinical development for nonsense mutation Duchenne and Becker muscular dystrophy and for nonsense mutation cystic fibrosis. The company completed a $30M financing to support continued late‑stage clinical development of ataluren. Backers listed include long‑term investors Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S and other existing investors. Led by CEO Stuart W. Peltz, Ph.D., PTC maintains an internal pipeline addressing rare genetic disorders, oncology and infectious diseases. The article provides no revenue or user metrics and does not specify the financing instrument beyond describing it as a financing. PTC Therapeutics is a South Plainfield, New Jersey–based drug development company focused on small-molecule therapies. Its anti-infective program targets life-threatening, multi-drug-resistant Gram-negative bacterial infections and is currently in lead optimization, advancing toward identification of a development candidate. The company received a $5 million Seeding Drug Discovery award from UK charity Wellcome Trust to support this work. The article cites CDC estimates that of 1.7 million hospital-acquired bacterial infections that cause or contribute to nearly 100,000 U.S. deaths annually, Gram-negative bacteria are responsible for more than 30 percent, underscoring clinical need. Last year PTC received a $5.4 million award to support its BMI1 oncology program, reflecting ongoing grant funding activity. In a separate deal last month, PTC entered a licensing agreement with Roche and the SMA Foundation granting Roche an exclusive worldwide license to PTC’s SMA program, which includes three preclinical compounds and potential backups, in a deal valued at up to $490 million. PTC Therapeutics is a South Plainfield, NJ-based biopharmaceutical company focused on orally administered small-molecule drugs that target post-transcriptional control processes. Its pipeline addresses multiple therapeutic areas including genetic disorders, oncology, and infectious diseases. The company's lead product candidate is ataluren, an investigational drug designed to enable formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. PTC is preparing to commercialize ataluren and views its launch as a potential new paradigm in treating genetic disorders. The company recently completed a $50M equity financing to increase financial flexibility as it advances toward commercialization. The financing included participation from both new and existing investors and resulted in Delphi Ventures' Deepa Pakianathan joining the board.

• CELLFOR

  Participated · Equity · Jul 2010

  CellFor is a Vancouver, British Columbia-based provider of varietal tree seedlings used for reforestation. The company closed an over $35m equity financing. The investment was led by new investor Capricorn Investment Group with participation from existing major partners. Its principal institutional investors include CSFB Equity Partners, LP, GrowthWorks Capital and BDC Venture Capital. CellFor operates U.S. offices in Georgia, South Carolina, Arkansas, Texas and Maine. Its conifer seedlings are planted across the southeastern U.S., Canada, Chile, New Zealand, Australia, Brazil, Argentina and Uruguay.

No current team members are available.